FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns application of tetrapeptide Leu-Ile-Lys-His, leucine-isoleucine-lysine-histidine, as agent for proteome correction of oxalate nephrolithiasis.
EFFECT: invention provides a wider range of methods for pharmacological correction of oxalate nephrolithiasis and high antilithogenic activity.
1 cl, 5 dwg, 4 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACOLOGICAL AGENT FOR URINARY STONE DISEASE TREATMENT | 2018 |
|
RU2679120C1 |
PHARMACOLOGICAL AGENT FOR THE TREATMENT OF URATE NEPHROPATHY | 2021 |
|
RU2760949C1 |
REMEDY FOR THE TREATMENT OF URATE NEPHROLITHIASIS | 2021 |
|
RU2762139C1 |
METHOD FOR PREDICTING URATE NEPHROLITHIASIS | 2021 |
|
RU2759237C1 |
AGENT ANTILITAL POSSESSING ANTILITOGENIC ACTION | 2012 |
|
RU2484834C1 |
PROCESS FOR PREPARATION OF A PEPTIDE AGENT WITH ANTILITHOGENIC EFFECT | 2017 |
|
RU2652339C1 |
METHOD FOR PREDICTION OF URINARY STONE DISEASE | 2010 |
|
RU2451935C1 |
AGENT STIMULATING FILTRATION AND EXCRETORY FUNCTION OF KIDNEY AT TOXIC NEPHROPATHOLOGY | 1992 |
|
RU2008912C1 |
METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
METHOD FOR THERAPY AND PREVENTION OF PROGRESSION OF CHRONIC RENAL FAILURE | 2021 |
|
RU2763661C2 |
Authors
Dates
2019-10-23—Published
2019-01-09—Filed